Pompe Disease

Definition

Pompe disease (glycogen storage disease type II) is a lysosomal glycogen-storage disorder caused by biallelic loss-of-function mutations in the GAA gene encoding acid α-glucosidase (GAA). GAA deficiency leads to lysosomal glycogen accumulation in cardiac muscle, skeletal muscle, and — in severe cases — the central nervous system. Infantile-onset Pompe disease (IOPD) is the most severe form; without treatment, median time from diagnosis to death is approximately 2 months, with patients rarely surviving beyond 1 year.

Key Concepts

Pathophysiology

• Biallelic GAA mutations cause loss of functional acid α-glucosidase → lysosomal glycogen accumulation in cardiac and skeletal myocytes
• Infantile-onset (IOPD): Cardiomegaly, hypotonia, respiratory failure, multiorgan involvement; onset in utero or early infancy
• Late-onset: Predominantly skeletal myopathy and respiratory failure; cardiac involvement mild or absent
• Untreated IOPD: natural history shows rapid deterioration — median death 2 months from diagnosis; most patients lose ability to sit without support and develop progressive LV posterior wall thickening (sources/aav9-pompe-nejm-2025, rating: high)

CRIM Status

• Cross-reactive immunologic material (CRIM) status: Predicts immune response to ERT
  • CRIM-positive patients express residual structurally related GAA protein → tolerate rhGAA
  • CRIM-negative patients (no residual GAA) mount high sustained anti-rhGAA IgG titers → significantly worse outcomes with ERT
• CRIM status determined by genotype; negative CRIM associated with worse prognosis even with ERT (sources/aav9-pompe-nejm-2025, rating: high)
• Immune-tolerance induction (ITI) used pre-ERT in CRIM-negative patients to prevent antibody formation

Standard Treatment: Enzyme-Replacement Therapy (ERT)

• rhGAA (alglucosidase alfa): Recombinant human GAA administered IV every 2 weeks (standard dose 20 mg/kg)
• ERT has prolonged survival in IOPD but has critical limitations:
  1. Cannot cross the blood–brain barrier → does not address CNS glycogen accumulation; white matter abnormalities develop from ~2 years of age; cognitive decline in long-term survivors (sources/aav9-pompe-nejm-2025, rating: high)
  2. Short half-life (2–9 days): Requires repeated lifelong infusions
  3. Immunogenicity: Both CRIM-positive and CRIM-negative patients develop anti-rhGAA IgG, reducing efficacy over time (sources/aav9-pompe-nejm-2025, rating: high)
  4. No CNS benefit: ERT-treated patients who survive into adolescence/adulthood can have progressive cognitive decline from cerebral glycogen accumulation

Gene Therapy Approach: GC301 (rAAV9-coGAA)

• GC301 (Genecradle Therapeutics): Recombinant AAV9 carrying codon-optimized human GAA cDNA
• Composite promoter: CMV early enhancer + chicken β-actin promoter + TAF1 intron-derived 5' UTR → ubiquitous tissue expression
• Dose: 1.2 × 10¹⁴ vg/kg single IV infusion; prophylactic prednisolone co-administered
• AAV9 advantages over rhGAA:
  • Crosses the blood–brain barrier → potential CNS GAA expression
  • Single administration → avoids repeated IV infusions and cumulative antibody development
  • Persistent expression → GAA levels remain elevated months after infusion
• Clinical results (n=4 infants; ChiCTR2200063229): 3/4 patients survived 52 weeks with improved cardiac outcomes (LVM index reduction, LVEF preservation) and psychomotor development (HINE scores normalized in 2 patients by 12 months); Patients 3 and 4 walked without assistance by 22–25 months post-infusion (sources/aav9-pompe-nejm-2025, rating: high)

Immune Tolerance to Transgenic GAA — Critical Finding

• Anti-GAA antibodies were not detected in any patient throughout the 52-week observation period following GC301 — in contrast to the universal anti-rhGAA IgG seen with ERT
• GAA-specific cellular immune responses (IFN-γ ELISpot) also absent in all patients
• Mechanism of immune tolerance to AAV-delivered transgenic products: incompletely understood; negative immune responses to transgene are reported with other AAV therapies; may involve hepatic cross-presentation or regulatory T-cell induction (sources/aav9-pompe-nejm-2025, rating: high)

CNS Involvement and AAV9 Blood–Brain Barrier Penetration

• rhGAA cannot cross the blood–brain barrier; cerebral glycogen accumulation in IOPD survivors on ERT causes white matter changes from ~2 years and progressive cognitive decline (sources/aav9-pompe-nejm-2025, rating: high)
• AAV9 has demonstrated CNS transduction in preclinical studies (mice, non-human primates); clinical evidence: HINE scores normalized by 12 months in 2 patients (Patients 3, 4), consistent with CNS GAA expression
• Long-term neurological and cognitive outcomes with GC301 not yet established; further studies required

Cardiac Outcomes in IOPD

• Presenting feature: marked cardiomegaly with LV posterior wall and IVS thickening; elevated LVM index (z-score >13 at baseline in Patient 1)
• GC301: LVM index decreased from 157 → 68 g/m² over 24 weeks (Patient 1); LVEF improved in 3/4 patients
• Respiratory infections worsen cardiac function: LVM index increased during intercurrent pneumonia in Patients 1, 2, 3 — infection management is a key component of overall care (sources/aav9-pompe-nejm-2025, rating: high)
• Infections also reduced GAA activity in blood (Patient 1) — suggesting inflammation impairs gene expression or clearance increases

Role of Early Diagnosis and Utero Treatment

• Newborn screening programs allow early ERT initiation before symptom onset → better outcomes
• In utero ERT reported in one case (better outcomes than affected siblings treated after birth) — highlights importance of prenatal diagnosis
• Preterm delivery with prenatal disease onset (as in Patient 2 of GC301 trial) is associated with worse prognosis; in utero gene therapy is a future possibility

Contradictions / Open Questions

• Anti-GAA immune tolerance mechanism: Why does AAV9-delivered GAA not trigger the same antibody responses as IV rhGAA? Hepatic expression and cross-presentation of the transgene may induce regulatory tolerance — but this is unproven and may not hold in CRIM-negative patients or at different doses (sources/aav9-pompe-nejm-2025, rating: high)
• CNS benefit vs. durability: AAV9 crosses the blood–brain barrier and HINE scores normalize — but whether episomal AAV9 in CNS cells provides durable GAA expression as the patient grows is unknown. Paediatric cardiomyocyte and neuronal division dilutes episomal transgene, potentially reducing CNS efficacy over years
• Respiratory infections and gene therapy: All 4 patients experienced pneumonia; infections reduced GAA activity and worsened cardiac function. Whether infection susceptibility is inherent to Pompe disease airway involvement, the residual "immunity gap" from COVID-19 social isolation, or an AAV9 effect on immune competence remains unresolved (sources/aav9-pompe-nejm-2025, rating: high)
• Re-dosing impossibility: Anti-AAV9 IgG developed in all patients after GC301 infusion. If therapeutic effect wanes (episomal dilution, infection-related loss), re-dosing with AAV9 is precluded by pre-existing immunity — a critical limitation for a lifelong disease starting in infancy
• CRIM-negative patients: All 3 tested patients were CRIM-positive; CRIM status of Patient 1 was uncertain. Whether immune tolerance to transgenic GAA extends to CRIM-negative patients (who have no endogenous GAA protein) requires specific evaluation

Connections

• Related to concepts/AAV-Gene-Delivery
• Related to concepts/Anderson-Fabry-Disease (other lysosomal storage disorder with cardiac involvement)
• Related to entities/Genecradle-Therapeutics

Sources

• sources/aav9-pompe-nejm-2025